ABUS vs. ALT, KALV, KMDA, FSTX, MGTA, RNA, JANX, ACAD, ARVN, and BHC
Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Altimmune (ALT), KalVista Pharmaceuticals (KALV), Kamada (KMDA), F-star Therapeutics (FSTX), Magenta Therapeutics (MGTA), Avidity Biosciences (RNA), Janux Therapeutics (JANX), ACADIA Pharmaceuticals (ACAD), Arvinas (ARVN), and Bausch Health Companies (BHC). These companies are all part of the "medical" sector.
Altimmune (NASDAQ:ALT) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership.
Arbutus Biopharma received 376 more outperform votes than Altimmune when rated by MarketBeat users. Likewise, 70.83% of users gave Arbutus Biopharma an outperform vote while only 70.00% of users gave Altimmune an outperform vote.
78.1% of Altimmune shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 4.1% of Altimmune shares are owned by insiders. Comparatively, 4.0% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Altimmune presently has a consensus price target of $17.25, suggesting a potential upside of 129.69%. Arbutus Biopharma has a consensus price target of $4.33, suggesting a potential upside of 28.97%. Given Arbutus Biopharma's higher possible upside, analysts plainly believe Altimmune is more favorable than Arbutus Biopharma.
Arbutus Biopharma has a net margin of -572.81% compared to Arbutus Biopharma's net margin of -22,645.37%. Arbutus Biopharma's return on equity of -46.96% beat Altimmune's return on equity.
Arbutus Biopharma has higher revenue and earnings than Altimmune. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.
Altimmune has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.
In the previous week, Altimmune had 10 more articles in the media than Arbutus Biopharma. MarketBeat recorded 15 mentions for Altimmune and 5 mentions for Arbutus Biopharma. Altimmune's average media sentiment score of 0.75 beat Arbutus Biopharma's score of 0.36 indicating that Arbutus Biopharma is being referred to more favorably in the news media.
Summary
Arbutus Biopharma beats Altimmune on 9 of the 17 factors compared between the two stocks.
Get Arbutus Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arbutus Biopharma Competitors List
Related Companies and Tools
